Gapping up
In reaction to strong earnings/guidance: QTM +13.7%, SWKS +7.6%, DFRG +7%, DPZ +3%, TC +2.6%, JNJ +1.4%, C +1.1%, HSON +0.5%
M&A news: CSX +0.9% (WSJ discusses that Canadian Pacific (CP) merger with CSX is still possible, while Reuters piece is cautious on the merger, initiated with a Buy at UBS)
Select Ebola related names showing strength: NLNK +8.3%, NNVC +5%, INO +4.6%, HEB +2.7%, SRPT +1.5%
Other news: SMED +8.1% (cont vol), GALE +7% (receives notice of allowance of improvement patent for NeuVax (nelipepimut-S) in Japan), LAKE +6.9% (following 45% move higher yesterday with ongoing Ebola concerns), APT +5.8% (following 35% move higher yesterday with ongoing Ebola concerns), PBMD +5.1% (disclosed that Immutep received a Notice of Allowance from Australian Patent Office for Patent Application AU 2008306576), HZNP +4.9% (co reviewed opportunities for ACTIMMUNE: potential for $500 mln or greater in peak annual sales if approved by the FDA for Friedreich's Ataxia), SUNE +4% (amends letter of credit facility to $800 mln USD for credit commitments and future increases), JRJC +2.6% (releases enhanced mobile application), MBLY +2.1% (still checking), MU +1.9% (Samsung Elect CEO downplayed fears of increased competition in chip space after co last week announced plans for new factory, which took down Micron last wk), RIO +1.8% (may be in sympathy after BHP upgrade), SDRL +1.5% (still checking), DRYS +1.4% (modest pull back following yest's 17% slide), YHOO +1.4% (may be related to Alibaba (BABA) upgrade),PCRX +1.1% (announces additional data supporting safety of EXPAREL in peripheral nerve block)
Analyst comments: BHP +1.9% (upgraded to Neutral from Underperform at Credit Suisse), ETN +1.3% (upgraded to Overweight from Equal Weight at Barclays), VOD +0.8% (initiated with a Buy at Deutsche Bank), EOG +0.7% (upgraded to Outperform from Mkt Perform at Bernstein), AAPL +0.7% (target raised to $110 from $96 at Credit Suisse
)
In reaction to strong earnings/guidance: QTM +13.7%, SWKS +7.6%, DFRG +7%, DPZ +3%, TC +2.6%, JNJ +1.4%, C +1.1%, HSON +0.5%
M&A news: CSX +0.9% (WSJ discusses that Canadian Pacific (CP) merger with CSX is still possible, while Reuters piece is cautious on the merger, initiated with a Buy at UBS)
Select Ebola related names showing strength: NLNK +8.3%, NNVC +5%, INO +4.6%, HEB +2.7%, SRPT +1.5%
Other news: SMED +8.1% (cont vol), GALE +7% (receives notice of allowance of improvement patent for NeuVax (nelipepimut-S) in Japan), LAKE +6.9% (following 45% move higher yesterday with ongoing Ebola concerns), APT +5.8% (following 35% move higher yesterday with ongoing Ebola concerns), PBMD +5.1% (disclosed that Immutep received a Notice of Allowance from Australian Patent Office for Patent Application AU 2008306576), HZNP +4.9% (co reviewed opportunities for ACTIMMUNE: potential for $500 mln or greater in peak annual sales if approved by the FDA for Friedreich's Ataxia), SUNE +4% (amends letter of credit facility to $800 mln USD for credit commitments and future increases), JRJC +2.6% (releases enhanced mobile application), MBLY +2.1% (still checking), MU +1.9% (Samsung Elect CEO downplayed fears of increased competition in chip space after co last week announced plans for new factory, which took down Micron last wk), RIO +1.8% (may be in sympathy after BHP upgrade), SDRL +1.5% (still checking), DRYS +1.4% (modest pull back following yest's 17% slide), YHOO +1.4% (may be related to Alibaba (BABA) upgrade),PCRX +1.1% (announces additional data supporting safety of EXPAREL in peripheral nerve block)
Analyst comments: BHP +1.9% (upgraded to Neutral from Underperform at Credit Suisse), ETN +1.3% (upgraded to Overweight from Equal Weight at Barclays), VOD +0.8% (initiated with a Buy at Deutsche Bank), EOG +0.7% (upgraded to Outperform from Mkt Perform at Bernstein), AAPL +0.7% (target raised to $110 from $96 at Credit Suisse
)